Sustained compensatory p38 MAPK signaling following treatment with MAPK inhibitors induces the immunosuppressive protein CD73 in cancer: combined targeting could improve outcomes

por Mikkel G. Terp, Odd L. Gammelgaard, Henriette Vever, Morten F. Gjerstorff, Henrik J. Ditzel
Publicado 2021

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells

por Mikkel G. Terp, Kirstine Jacobsen, Miguel Angel Molina, Niki Karachaliou, Hans C. Beck, Jordi Bertran-Alamillo, Ana Giménez-Capitán, Andrés F. Cardona, Rafael Rosell, Henrik J. Ditzel
Publicado 2021

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

por Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publicado 2021

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

por Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Publicado 2021